Fusion Antibodies plc announced the formation of a new Scientific Advisory Panel of leading experts to support the company's research and development across its range of antibody services, and to provide advice regarding emerging science and technology issues and trends. Matthew Baker, PhD (NeoPhore); Professor Terry Rabbitts (Institute of Cancer Research); Professor Charlotte Deane (University of Oxford). Matthew Baker, PhD has more than 20 years' experience developing biologics in biotech and pharma companies and is a research expert in B- and T-cell immunology, including drug immunogenicity.

He was the Chief Scientific Officer of Abzena until 2016 and previously held a Non-Executive Director role at Oxgene. He is currently the CEO of NeoPhore. Matthew brings detailed immunology and virus-based mammalian display knowledge to the SAP as well as industry and market insight.

Professor Terry Rabbitts is a Professor of Immunology at the Institute of Cancer Research in London (UK), where he focuses on developing technologies using intracellular antibody fragments and small molecule derivatives, mainly aimed at targeting chromosomal translocation protein products. Terry is the ex-Chair of Cambridge Antibody Technology's Scientific Advisory Board, holding this position from launch until its IPO on the London Stock Exchange and is currently an advisor to several start-up biotech companies. He is also co-founder of both Orbit Discovery and Quadrucept Bio Ltd. Professor Charlotte Deane is a Professor of Structural Bioinformatics at the University of Oxford.

Her research in the Oxford Protein Informatics Group covers several areas in protein structure and interaction networks, combining both theoretical and empirical analysis. Her detailed expertise means she will bring structural modelling, bioinformatics and library design experience to the SAP, as well as an insight key to the development of future machine learning algorithms.